(GS71) GSK - Ratings and Ratios
Exchange: XETRA •
Country: United Kingdom •
Currency: EUR •
Type: Common Stock •
ISIN: GB00BN7SWP63
Vaccines, Specialty Medicines, General Medicines, Oncology, Respiratory
Dividends
| Dividend Yield | 4.07% |
| Yield on Cost 5y | 6.76% |
| Yield CAGR 5y | -6.54% |
| Payout Consistency | 95.2% |
| Payout Ratio | 48.6% |
| Risk via 10d forecast | |
|---|---|
| Volatility | 24.0% |
| Value at Risk 5%th | 36.3% |
| Relative Tail Risk | -8.16% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.98 |
| Alpha | 26.99 |
| CAGR/Max DD | 0.41 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.522 |
| Beta | -0.098 |
| Beta Downside | 0.056 |
| Drawdowns 3y | |
|---|---|
| Max DD | 27.82% |
| Mean DD | 9.10% |
| Median DD | 7.63% |
Description: GS71 GSK December 03, 2025
GSK plc (XETRA:GS71) develops, manufactures, and markets vaccines, specialty medicines, and general medicines across the UK, US, and global markets, operating through Commercial Operations and Total R&D segments. Its specialty portfolio targets oncology, respiratory-immunology, inflammation, and infectious diseases, while its vaccine suite spans shingles, RSV, HPV, and a broad range of pediatric and adult indications.
Key recent metrics: FY 2023 revenue of £34.1 bn, with vaccine sales up ≈ 9 % YoY driven by RSV and shingles growth; R&D spend at £5.4 bn (≈ 16 % of revenue), reflecting a pipeline that includes a Phase III ovarian-cancer candidate and mRNA vaccine collaborations with CureVac. Sector-wide drivers such as aging populations in Europe and North America and rising demand for mRNA platforms are expected to sustain top-line expansion, while pricing pressure in the US generic market remains a headwind.
For a data-driven, independent valuation perspective, a quick look at the free analytics on ValueRay may help you deepen your analysis.
Piotroski VR‑10 (Strict, 0-10) 5.5
| Net Income (5.49b TTM) > 0 and > 6% of Revenue (6% = 1.93b TTM) |
| FCFTA 0.08 (>2.0%) and ΔFCFTA -0.60pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue -10.86% (prev -13.29%; Δ 2.43pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.13 (>3.0%) and CFO 7.79b > Net Income 5.49b (YES >=105%, WARN >=100%) |
| Net Debt (12.19b) to EBITDA (12.18b) ratio: 1.00 <= 3.0 (WARN <= 3.5) |
| Current Ratio 0.84 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (4.03b) change vs 12m ago -1.33% (target <= -2.0% for YES) |
| Gross Margin 72.27% (prev 71.55%; Δ 0.72pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 53.88% (prev 53.94%; Δ -0.05pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 13.77 (EBITDA TTM 12.18b / Interest Expense TTM 657.0m) >= 6 (WARN >= 3) |
Altman Z'' 1.41
| (A) -0.06 = (Total Current Assets 17.84b - Total Current Liabilities 21.33b) / Total Assets 61.34b |
| (B) 0.16 = Retained Earnings (Balance) 10.02b / Total Assets 61.34b |
| (C) 0.15 = EBIT TTM 9.05b / Avg Total Assets 59.69b |
| (D) 0.22 = Book Value of Equity 10.02b / Total Liabilities 45.59b |
| Total Rating: 1.41 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 80.14
| 1. Piotroski 5.50pt |
| 2. FCF Yield 5.55% |
| 3. FCF Margin 14.60% |
| 4. Debt/Equity 0.98 |
| 5. Debt/Ebitda 1.00 |
| 6. ROIC - WACC (= 37.52)% |
| 7. RoE 37.40% |
| 8. Rev. Trend 63.64% |
| 9. EPS Trend -7.24% |
What is the price of GS71 shares?
As of December 11, 2025, the stock is trading at EUR 20.57 with a total of 87,320 shares traded.
Over the past week, the price has changed by -2.00%, over one month by +2.58%, over three months by +20.16% and over the past year by +27.47%.
Over the past week, the price has changed by -2.00%, over one month by +2.58%, over three months by +20.16% and over the past year by +27.47%.
Is GS71 a buy, sell or hold?
GSK has no consensus analysts rating.
What are the forecasts/targets for the GS71 price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | - | - |
| Analysts Target Price | - | - |
| ValueRay Target Price | 20.3 | -1.6% |
GS71 Fundamental Data Overview December 11, 2025
Market Cap USD = 95.95b (82.43b EUR * 1.164 EUR.USD)
Market Cap GBP = 72.01b (82.43b EUR * 0.8736 EUR.GBP)
P/E Trailing = 13.4342
P/E Forward = 9.3897
P/S = 2.5626
P/B = 4.5182
P/EG = 0.4172
Beta = 0.23
Revenue TTM = 32.17b GBP
EBIT TTM = 9.05b GBP
EBITDA TTM = 12.18b GBP
Long Term Debt = 13.70b GBP (from longTermDebt, last fiscal year)
Short Term Debt = 2.18b GBP (from shortLongTermDebt, last fiscal year)
Debt = 15.88b GBP (Calculated: Short Term 2.18b + Long Term 13.70b)
Net Debt = 12.19b GBP (from netDebt column, last fiscal year)
Enterprise Value = 84.60b GBP (72.01b + Debt 15.88b - CCE 3.30b)
Interest Coverage Ratio = 13.77 (Ebit TTM 9.05b / Interest Expense TTM 657.0m)
FCF Yield = 5.55% (FCF TTM 4.70b / Enterprise Value 84.60b)
FCF Margin = 14.60% (FCF TTM 4.70b / Revenue TTM 32.17b)
Net Margin = 17.08% (Net Income TTM 5.49b / Revenue TTM 32.17b)
Gross Margin = 72.27% ((Revenue TTM 32.17b - Cost of Revenue TTM 8.92b) / Revenue TTM)
Gross Margin QoQ = 73.58% (prev 72.89%)
Tobins Q-Ratio = 1.38 (Enterprise Value 84.60b / Total Assets 61.34b)
Interest Expense / Debt = 1.05% (Interest Expense 167.0m / Debt 15.88b)
Taxrate = 12.70% (312.0m / 2.46b)
NOPAT = 7.90b (EBIT 9.05b * (1 - 12.70%))
Current Ratio = 0.84 (Total Current Assets 17.84b / Total Current Liabilities 21.33b)
Debt / Equity = 0.98 (Debt 15.88b / totalStockholderEquity, last quarter 16.15b)
Debt / EBITDA = 1.00 (Net Debt 12.19b / EBITDA 12.18b)
Debt / FCF = 2.60 (Net Debt 12.19b / FCF TTM 4.70b)
Total Stockholder Equity = 14.69b (last 4 quarters mean from totalStockholderEquity)
RoA = 8.96% (Net Income 5.49b / Total Assets 61.34b)
RoE = 37.40% (Net Income TTM 5.49b / Total Stockholder Equity 14.69b)
RoCE = 31.87% (EBIT 9.05b / Capital Employed (Equity 14.69b + L.T.Debt 13.70b))
RoIC = 42.33% (NOPAT 7.90b / Invested Capital 18.66b)
WACC = 4.80% (E(72.01b)/V(87.89b) * Re(5.66%) + D(15.88b)/V(87.89b) * Rd(1.05%) * (1-Tc(0.13)))
Discount Rate = 5.66% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 8.05%
Shares Correlation 3-Years: -33.33 | Cagr: -0.37%
[DCF Debug] Terminal Value 76.27% ; FCFE base≈4.73b ; Y1≈4.17b ; Y5≈3.42b
Fair Price DCF = 15.40 (DCF Value 62.18b / Shares Outstanding 4.04b; 5y FCF grow -14.71% → 3.0% )
EPS Correlation: -7.24 | EPS CAGR: 29.19% | SUE: 0.04 | # QB: 0
Revenue Correlation: 63.64 | Revenue CAGR: 8.62% | SUE: N/A | # QB: 0
Market Cap GBP = 72.01b (82.43b EUR * 0.8736 EUR.GBP)
P/E Trailing = 13.4342
P/E Forward = 9.3897
P/S = 2.5626
P/B = 4.5182
P/EG = 0.4172
Beta = 0.23
Revenue TTM = 32.17b GBP
EBIT TTM = 9.05b GBP
EBITDA TTM = 12.18b GBP
Long Term Debt = 13.70b GBP (from longTermDebt, last fiscal year)
Short Term Debt = 2.18b GBP (from shortLongTermDebt, last fiscal year)
Debt = 15.88b GBP (Calculated: Short Term 2.18b + Long Term 13.70b)
Net Debt = 12.19b GBP (from netDebt column, last fiscal year)
Enterprise Value = 84.60b GBP (72.01b + Debt 15.88b - CCE 3.30b)
Interest Coverage Ratio = 13.77 (Ebit TTM 9.05b / Interest Expense TTM 657.0m)
FCF Yield = 5.55% (FCF TTM 4.70b / Enterprise Value 84.60b)
FCF Margin = 14.60% (FCF TTM 4.70b / Revenue TTM 32.17b)
Net Margin = 17.08% (Net Income TTM 5.49b / Revenue TTM 32.17b)
Gross Margin = 72.27% ((Revenue TTM 32.17b - Cost of Revenue TTM 8.92b) / Revenue TTM)
Gross Margin QoQ = 73.58% (prev 72.89%)
Tobins Q-Ratio = 1.38 (Enterprise Value 84.60b / Total Assets 61.34b)
Interest Expense / Debt = 1.05% (Interest Expense 167.0m / Debt 15.88b)
Taxrate = 12.70% (312.0m / 2.46b)
NOPAT = 7.90b (EBIT 9.05b * (1 - 12.70%))
Current Ratio = 0.84 (Total Current Assets 17.84b / Total Current Liabilities 21.33b)
Debt / Equity = 0.98 (Debt 15.88b / totalStockholderEquity, last quarter 16.15b)
Debt / EBITDA = 1.00 (Net Debt 12.19b / EBITDA 12.18b)
Debt / FCF = 2.60 (Net Debt 12.19b / FCF TTM 4.70b)
Total Stockholder Equity = 14.69b (last 4 quarters mean from totalStockholderEquity)
RoA = 8.96% (Net Income 5.49b / Total Assets 61.34b)
RoE = 37.40% (Net Income TTM 5.49b / Total Stockholder Equity 14.69b)
RoCE = 31.87% (EBIT 9.05b / Capital Employed (Equity 14.69b + L.T.Debt 13.70b))
RoIC = 42.33% (NOPAT 7.90b / Invested Capital 18.66b)
WACC = 4.80% (E(72.01b)/V(87.89b) * Re(5.66%) + D(15.88b)/V(87.89b) * Rd(1.05%) * (1-Tc(0.13)))
Discount Rate = 5.66% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 8.05%
Shares Correlation 3-Years: -33.33 | Cagr: -0.37%
[DCF Debug] Terminal Value 76.27% ; FCFE base≈4.73b ; Y1≈4.17b ; Y5≈3.42b
Fair Price DCF = 15.40 (DCF Value 62.18b / Shares Outstanding 4.04b; 5y FCF grow -14.71% → 3.0% )
EPS Correlation: -7.24 | EPS CAGR: 29.19% | SUE: 0.04 | # QB: 0
Revenue Correlation: 63.64 | Revenue CAGR: 8.62% | SUE: N/A | # QB: 0